- Home
- HIMS vs JAZZ Comparison
HIMS vs JAZZ Comparison
Compare HIMS & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIMS
- JAZZ
- Stock Information
- Founded
- HIMS 2017
- JAZZ 2003
- Country
- HIMS United States
- JAZZ Ireland
- Employees
- HIMS N/A
- JAZZ N/A
- Industry
- HIMS Medical/Nursing Services
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- HIMS Health Care
- JAZZ Health Care
- Exchange
- HIMS Nasdaq
- JAZZ Nasdaq
- Market Cap
- HIMS 6.6B
- JAZZ 6.5B
- IPO Year
- HIMS N/A
- JAZZ 2007
- Fundamental
- Price
- HIMS $26.19
- JAZZ $122.97
- Analyst Decision
- HIMS Buy
- JAZZ Buy
- Analyst Count
- HIMS 14
- JAZZ 14
- Target Price
- HIMS $23.71
- JAZZ $173.93
- AVG Volume (30 Days)
- HIMS 16.7M
- JAZZ 646.0K
- Earning Date
- HIMS 11-04-2024
- JAZZ 11-06-2024
- Dividend Yield
- HIMS N/A
- JAZZ N/A
- EPS Growth
- HIMS N/A
- JAZZ 458.10
- EPS
- HIMS 0.44
- JAZZ 7.04
- Revenue
- HIMS $1,241,994,000.00
- JAZZ $3,992,712,000.00
- Revenue This Year
- HIMS $71.33
- JAZZ $7.51
- Revenue Next Year
- HIMS $37.95
- JAZZ $6.82
- P/E Ratio
- HIMS $58.94
- JAZZ $17.48
- Revenue Growth
- HIMS 56.70
- JAZZ 5.23
- 52 Week Low
- HIMS $8.09
- JAZZ $99.06
- 52 Week High
- HIMS $35.02
- JAZZ $134.17
- Technical
- Relative Strength Index (RSI)
- HIMS 44.33
- JAZZ 54.14
- Support Level
- HIMS $24.62
- JAZZ $119.14
- Resistance Level
- HIMS $33.14
- JAZZ $125.77
- Average True Range (ATR)
- HIMS 2.70
- JAZZ 3.19
- MACD
- HIMS -0.92
- JAZZ -0.27
- Stochastic Oscillator
- HIMS 15.26
- JAZZ 55.59
About HIMS Hims & Hers Health Inc.
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.